Did you receive a metal-on-metal hip implant manufactured by stryker? Have you experienced complications from the device?

Call Today: (888) 207-0382

Blog

The Louisiana court overseeing thousands of Xarelto bleeding lawsuits has scheduled a hearing for January 30, 2018, following bellwether trials that concluded in December 2017. Two weeks prior to the hearing, the parties are instructed to submit joint briefs proposing how the federal litigation should proceed. Over 19,000 claims have been filed in this federal …. Read More

On December 5, 2017, an Indiana couple won a lawsuit against Johnson & Johnson and Bayer over the companies’ failure to instruct on how to avoid internal bleeding risks of their blockbuster blood thinner, Xarelto. A Philadelphia jury handed down the $27.8 million verdict for plaintiffs suing over serious health complications alleged to be caused …. Read More

Reports of injuries and deaths caused by the controversial oral blood thinner Xarelto continue to climb, according to a recent study by the Institute for Safe Medication Practices (ISMP). ISMP found that drugs such as Xarelto caused more emergency room visits in 2016 than any other class of drugs. Xarelto alone is reportedly responsible for …. Read More

The first bellwether trial concerning controversial anticoagulant Xarelto has begun in the Eastern District of Louisiana. The late-April 2017 trial is one of four bellwether trials scheduled to take place throughout this spring and summer. The cases all similarly allege that the drug’s manufacturer Janssen Pharmaceuticals did not adequately warn patients about the uncontrollable bleeding …. Read More

With more than 16,000 Xarelto bleeding lawsuits pending in the Eastern District of Louisiana, two motions for partial summary judgment have been denied by U.S. District Judge Eldon Fallon, the judge presiding over the Xarelto multidistrict litigation or MDL. The motions were filed by manufacturers of the blood-thinner drug, Johnson & Johnson subsidiary Janssen Pharmaceuticals, …. Read More